STOCK TITAN

Intelgenx Technologies Corp - IGXT STOCK NEWS

Welcome to our dedicated page for Intelgenx Technologies news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on Intelgenx Technologies stock.

Intelgenx Technologies Corp (IGXT) specializes in advanced drug delivery solutions for pharmaceutical partners worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's proprietary technologies, strategic collaborations, and regulatory progress.

Track critical developments including formulation advancements, clinical trial milestones, manufacturing expansions, and partnership announcements. Our curated collection ensures timely access to verified press releases and objective reporting on IGXT's role in enhancing therapeutic outcomes through innovative delivery systems.

Discover updates spanning key operational areas: regulatory submissions for improved drug formulations, strategic licensing agreements with global partners, and manufacturing scale-up initiatives for optimized production. Bookmark this page for direct access to Intelgenx's official communications and third-party analyses of their pharmaceutical development progress.

Rhea-AI Summary
IntelGenx Technologies Corp. (IGX) reported a revenue of $318,000 for Q3-2023, with a net comprehensive loss of $2.5 million. Recent developments include receiving a purchase order for RIZAFILM® from Gensco Pharma, and completing patient enrollment for a clinical trial of Montelukast VersaFilm® in Alzheimer’s patients. The company also announced several other positive developments, including a research collaboration with Karolinska University Hospital for the treatment of Parkinson’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IntelGenx Corp. has announced a further amendment to their agreement with Tilray Brands Inc. for the co-development and commercialization of cannabinoid-infused VersaFilm® products. The amendment includes an initial purchase order for three SKUs totaling 130,000 filmstrips and allows for the co-development and commercialization of CBD, THC, and combination THC:CBD products with additional partners. The agreement also removes any royalties paid to or from Tilray.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
IntelGenx Technologies Corp. will release its third quarter 2023 financial results on November 9, 2023, after market close. The accompanying conference call will be hosted by the CEO, President, and Chairman to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
conferences earnings
Rhea-AI Summary
IntelGenx receives first purchase order for RIZAFILM® from Gensco Pharma, triggering upfront deposit and milestone payments. Expects to ship product in Q1-2024 for immediate launch. CEO expresses confidence in partnership and positive impact on balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
IntelGenx Corp. provides regulatory update on Buprenorphine Buccal Film. FDA grants priority review with goal date for review of the Amendment on March 8, 2024, unless inspection required. CEO optimistic about FDA decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
IntelGenx Technologies Corp. announces closing of non-brokered private placement with atai Life Sciences AG for gross proceeds of approximately US$3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
conferences earnings
Rhea-AI Summary
IntelGenx Corp. has completed patient enrollment in the Montelukast VersaFilm Phase 2a clinical trial for Alzheimer's Disease. The study enrolled 52 patients, 18 fewer than planned, with approval from Health Canada. The company aims to determine the extent of the drug's effect sizes and expects to complete the trial in Q1 2024 and report initial results in Q2 2024. The AD market is projected to reach $13.7 billion in 2030 with a compound annual growth rate of 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
Intelgenx Technologies Corp

OTC:IGXT

IGXT Rankings

IGXT Stock Data

29.69M
135.54M
22.4%
Biotechnology
Healthcare
Link
Canada
Montreal